NCT07895901Recruiting
Characterization of CD180 Protein Expression in Myeloid Hematological Malignancies by Flow Cytometry
Source: ClinicalTrials.gov · Last updated 26 Oct 2026
Brief summary (registry, in English)
CD180 is a cell-surface protein recently identified through proteomic analysis as a potential target of interest in myeloid hematological malignancies. It may have diagnostic and monitoring potential, particularly in acute myeloid leukemia (AML). This monocentric, non-interventional, retrospective observational study aims to characterize CD180 expression by flow cytometry in pathological hematopoietic cells, particularly in AML, and in normal hematopoietic stem and progenitor cells (CD34+ cells). The study will use residual blood and bone marrow samples collected during routine care and otherwise intended for disposal by incineration, together with relevant clinical and laboratory data.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 19 Oct 2026
- Start date
- Jan 2026
- Primary completion date
- Apr 2027
- Lead sponsor
- University Hospital, Strasbourg, France
- Diseases
- Acute myeloid leukemia, Childhood cancers
- NCT number
- NCT07895901
What you commit to
- Study type: Observational
- Planned participants: 50
- From Jan 2026 to the primary completion date, Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients and/or their legal representatives, where applicable, who have objected to the reuse of personal data for scientific research.
- Samples more than 72 hours old.
- Clotted samples.
- Samples with insufficient volume (less than 10 microliters).
Who the study is looking for
- Adult patients aged 18 years or older.
- Pediatric patients aged 1 to 17 years.
- Patients with confirmed or suspected acute myeloid leukemia who have undergone bone marrow aspiration as part of the diagnostic or relapse assessment.
- Patients whose stem cells are being assessed using a blood or bone marrow sample.
- Patients and/or their legal representatives, where applicable, informed by letter of the use of residual sample material for research purposes.
- No written objection documented in the medical record to the reuse of personal data for scientific research.
Age in the registry: 1 year to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Laboratoire d'Hématologie Biologique - CHU de Strasbourg - France Coordinator of this site? Confirm its status | Strasbourg | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.